Jeff Kraws Weighs In on Supreme Court Victory for Generic Drug Makers

Posted by Colleen Koski

April 19, 2012 at 3:03 AM

Novo Nordisk PrandinYesterday, Crystal Research CEO Jeffrey Kraws and NPR's correspondent Yuki Noguchi discussed the impact of a U.S. Supreme Court decision that allows generic drug makers to challenge brand-name rivals suspected of overstating the reach of their patents in regulatory filings. The full audio clip and transcript are available here.

Specifically, the decision allows generic drug company Caraco Pharmaceutical Laboratories to sue Novo Nordisk A/S (NVO-NYSE) for what Caraco describes as exaggerated descriptions of the scope of patents Novo Nordisk holds on the diabetes drug repaglinide (Prandin). 

Caraco seeks to sell a generic version of Novo Nordisk’s Prandin. Caraco and its parent company, Sun Pharmaceutical Industries Ltd., claim that Novo misrepresented the reach of one of its patents to the FDA and improperly extended its monopoly over Prandin until 2018. Caraco contends that the patent only covers the use of Prandin with metformin.

This decision handed a victory to generic drug companies and overturned a lower-court ruling that had prevented generic manufacturers from legally disputing such claims of brand-name rivals in similar scenarios.

About Jeffrey Kraws

Mr. Kraws is chief executive officer and co-founder of independent research firm Crystal Research Associates. He is well known by the international financial media and has often provided expert commentary for network news programs. Mr. Kraws' insight assists producers and anchors with providing credible analysis on a variety of cutting-edge topics related to the technology, mineral, healthcare, pharmaceutical, and biotechnology markets. His full biography is available here.

Please direct all media requests for interviews, expert commentary, or general inquiries to eio@crystalra.com. 

Topics: Crystal Research Associates, Novo Nordisk, generic drugs

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic